Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2011  |  Volume : 32  |  Issue : 1  |  Page : 25-29

Role of glutathione-s-transferase and CYP1A1*2A polymorphisms in the therapy outcome of south Indian acute lymphoblastic leukemia patients


1 Department of Molecular Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
2 Department of Hematology & Immunology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
3 Department of Biostatistics & Tumor Registry, Cancer Institute (WIA), Chennai, Tamil Nadu, India
4 Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India

Correspondence Address:
K Nirmala Nancy
Department of Molecular Oncology, Cancer Institute (WIA), No.38, Sardar Patel Road, Guindy, Chennai - 600 036, Tamil Nadu
India
Login to access the Email id

Source of Support: DST (DST No. SR/SO/HS-26/2004), Conflict of Interest: None


DOI: 10.4103/0971-5851.81886

Rights and Permissions

Background: Polymorphisms in the drug-metabolizing enzymes are found to be associated with the inter-individual variation in response to a particular drug. Glutathione S-transferases (GSTs) are involved in the metabolism of several anticancer drugs, including alkylating agents, anthracyclines, and cyclophosphamides. Aim: The present study is aimed to examine the association of GST and CYP1A1*2A polymorphisms in the susceptibility to acute lymphoblastic leukemia (ALL) and the prognostic significance. Materials and Methods: A total of 92 immunophenotyped patients and 150 cord blood controls were genotyped by PCR for GSTM1 and GSTT1, RQ-PCR allelic discrimination assay for GSTP1 and PCR-RFLP for CYP1A1*2A polymorphism. Results: We have previously reported the significant association of GSTM1 (null) and combined GSTP1 {(Ile/Val)/ (Val/Val)} /GSTM1 (null) genotype with the susceptibility to ALL. No significant association was observed with GSTT1 (P=0.75) and CYP1A1*2A (P=0.61 for +/- and P=0.86 for -/- respectively) in the susceptibility to ALL. Survival analysis was performed in 50 of the 92 patients who were followed for three years. Kaplan-Meier survival analysis for three years showed significant lower event-free survival in patients harboring GSTP1 (Ile/Val) and GSTP1 (Val/Val) (P=0.038 and 0.0001, respectively) genotype. Cox regression analysis revealed GSTP1 as an independent prognostic marker with 6-fold higher risk with Val/Val genotype (P=0.003). Conclusions: Our results show that GSTP1 (Ile/Val) polymorphism has a role in the susceptibility to ALL and also influence treatment outcome.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2695    
    Printed151    
    Emailed0    
    PDF Downloaded353    
    Comments [Add]    
    Cited by others 13    

Recommend this journal